Today's news and resulting trading brought up the
Post# of 72440
1. All the talk about the "market" and how it relates to IPIX is a load of pure BS. There is basically no market at the current time. You cannot have news that validates 50% of the trial (the safety side) on a drug that could provide an answer to a problem jeopardizing the world's economies and it spurs no large buying. We still have the same minuscule core trading this stock (wonder what the real volume was today without the wash trades, most likely less than 1MM IMO), and the pricing is being held just above $.25. Result is a continuing steal for those investors that recognize the power of Brilacidin and the fantastic risk/reward factor currently being seen for IPIX. I will continue to be buying.
2. As an aside to the "no market" statement above, those that are reading today's news appear to be blind to the fact (stated clearly in the PR) that Brilacidin is performing remarkably well not only in further investigation as to being a pan-corona virus solution but most likely will be the "gold standard" in treating ALL families of viruses. Anybody want to take a guess what the value of this feature should be worth to IPIX? Hint: Many billions.
3. There will likely be a day in the very near future when all the shorts (both legal and naked) will have to be cleared so that those holding them don't incur catastrophic losses. When that day comes, we will see that the trading games played over the last year(s) prove disastrous to short traders.
4. I have been a strong proponent that it is far, far too early to even consider a buyout of IPIX since Leo's price will be high and no BP at this time would consider meeting it - BUT with the advent that (a)Brilacidin is recognized as the ultimate virus killer, (b) , the upcoming UC and OM trials show it should also handle the entire GI tract, (c) the current trial shows B works great on respiratory issues and possibly tuberculosis issues in Russia, and this new arm of medicine (Defensin Mimetics) becomes the talk of the medical world that some BP will pull it's head out and realize capturing this drug would be in it's long term best interest, even at the steep asking price Leo will demand. I could see Leo selling the Brilacidin platform or, more likely, partnering the entire platform to one BP to keep revenues coming in for many years. This would allow IPIX to focus solely on Kevetrin and bring that monster drug to the same level of value as it has Brilacidin.
5. I now believe we see IPIX uplisted much earlier than I did even a few weeks ago.
IPIX is in the driver's seat and those trying to hold it back are putting themselves in extreme financial risk. Nice for long term holders to be able to sleep well at night and those that gave us sleepless nights for years are now on the rack.